Back
TransCode Therapeutics, Inc. 10K Form
Sell
22
RNAZ
TransCode Therapeutics, Inc.
Last Price:
$8.59
Seasonality Move:
-30.19%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive RNAZ News And Ratings
See the #1 stock for the next 7 days that we like better than RNAZ
RNAZ Financial Statistics
Sales & Book Value
| Annual Sales: | $0 |
|---|---|
| Cash Flow: | $-4.1M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $1.71 |
| Price / Book: | 4.92 |
Profitability
| EPS (TTM): | -242.07560 |
|---|---|
| Net Income (TTM): | $-27.1M |
| Gross Margin: | $-534.9K |
| Return on Equity: | -775.26% |
| Return on Assets: | -357.8% |
TransCode Therapeutics, Inc. Earnings Forecast
Key TransCode Therapeutics, Inc. Financial Ratios
-
Per Share Earnings over the last 6 years have been positive in 2 years.
TransCode Therapeutics, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | RNAZ |
| Website: | transcodetherapeutics.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 1.6 |
| Quick Ratio: | 0.96 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
RNAZ Technical Analysis vs Fundamental Analysis
Sell
22
TransCode Therapeutics, Inc. (RNAZ)
is a Sell
Is TransCode Therapeutics, Inc. a Buy or a Sell?
-
TransCode Therapeutics, Inc. stock is rated a SellThe current TransCode Therapeutics, Inc. [RNAZ] share price is $8.64. The Score for RNAZ is 22, which is 56% below its historic median score of 50, and infers higher risk than normal.